Long-term response on brentuximab vedotin therapy in patients with Hodgkin lymphoma
Affiliations- Oddział Hematologii Onkologicznej z Klinicznym Pododdziałem Przeszczepiania Szpiku, Szpital Specjalistyczny w Brzozowie, ul. ks. Bielawskiego, 36–200 Brzozów, Poland
open access
Abstract
Progress in Hodgkin lymphoma (HL) treatment has been achieved due to introduction of new diagnostic methods, disease staging, and new therapy implementations. In spite of it, some patients are challenging in diagnostic and therapeutic process. The topic will provide a brief review of 2 young patients with HL who failed to achieve remission following few therapeutic treatment lines. Both of them response has been achieved when brentuximab vedotin was used. Many patients requires up to date new diagnostic methods implementation. Their interpretation is possible only in the context of clinical data.
Abstract
Progress in Hodgkin lymphoma (HL) treatment has been achieved due to introduction of new diagnostic methods, disease staging, and new therapy implementations. In spite of it, some patients are challenging in diagnostic and therapeutic process. The topic will provide a brief review of 2 young patients with HL who failed to achieve remission following few therapeutic treatment lines. Both of them response has been achieved when brentuximab vedotin was used. Many patients requires up to date new diagnostic methods implementation. Their interpretation is possible only in the context of clinical data.
Keywords
Hodgkin lymphoma (HL), brentuksymab vedotin (BV), autologous hematopoietic stem cell transplantation
About this articleTitle
Long-term response on brentuximab vedotin therapy in patients with Hodgkin lymphoma
Journal
Hematology in Clinical Practice
Issue
Article type
Case report
Pages
17-20
Page views
388
Article views/downloads
127
DOI
10.5603/Hem.2019.0020
Keywords
Hodgkin lymphoma (HL)
brentuksymab vedotin (BV)
autologous hematopoietic stem cell transplantation
Authors
Andrzej Pluta
Justyna Gil
Jacek Krzanowski
Sławomir Radwański
